A new ACC Expert Consensus Decision Pathway aims to fill the gap in clinical care for the management of high-risk atherosclerotic cardiovascular disease (ASCVD) patients with persistent hypertriglyceridemia and the incorporation of triglyceride nonstatin therapies. The 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia, published July 28 in the Journal of the American College of Cardiology, provides recommendations for clinicians and patients regarding the use of statins and triglyceride nonstatin therapies to reduce the risk of ASCVD in patients with persistent hypertriglyceridemia who have established ASCVD, diabetes mellitus, severe hypertriglyceridemia and other high-risk factors. Read more.